3KM4

Optimization of Orally Bioavailable Alkyl Amine Renin Inhibitors


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.90 Å
  • R-Value Free: 0.261 
  • R-Value Work: 0.200 
  • R-Value Observed: 0.203 

wwPDB Validation   3D Report Full Report



Literature

Optimization of orally bioavailable alkyl amine renin inhibitors.

Xu, Z.Cacatian, S.Yuan, J.Simpson, R.D.Jia, L.Zhao, W.Tice, C.M.Flaherty, P.T.Guo, J.Ishchenko, A.Singh, S.B.Wu, Z.McKeever, B.M.Scott, B.B.Bukhtiyarov, Y.Berbaum, J.Mason, J.Panemangalore, R.Cappiello, M.G.Bentley, R.Doe, C.P.Harrison, R.K.McGeehan, G.M.Dillard, L.W.Baldwin, J.J.Claremon, D.A.

(2010) Bioorg Med Chem Lett 20: 694-699

  • DOI: 10.1016/j.bmcl.2009.11.066
  • Primary Citation of Related Structures:  
    3KM4

  • PubMed Abstract: 
  • Structure-guided drug design led to new alkylamine renin inhibitors with improved in vitro and in vivo potency. Lead compound 21a, has an IC(50) of 0.83nM for the inhibition of human renin in plasma (PRA). Oral administration of 21a at 10mg/kg result ...

    Structure-guided drug design led to new alkylamine renin inhibitors with improved in vitro and in vivo potency. Lead compound 21a, has an IC(50) of 0.83nM for the inhibition of human renin in plasma (PRA). Oral administration of 21a at 10mg/kg resulted in >20h reduction of blood pressure in a double transgenic rat model of hypertension.


    Organizational Affiliation

    Vitae Pharmaceuticals, 502 West Office Center Drive, Fort Washington, PA 19034, USA.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
ReninAB337Homo sapiensMutation(s): 0 
Gene Names: HUMAN_RENINREN
EC: 3.4.23.15
Find proteins for P00797 (Homo sapiens)
Explore P00797 
Go to UniProtKB:  P00797
NIH Common Fund Data Resources
PHAROS  P00797
Protein Feature View
Expand
  • Reference Sequence
Oligosaccharides

Help

Entity ID: 2
MoleculeChainsChain Length2D Diagram Glycosylation3D Interactions
2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
C
2 N-Glycosylation Oligosaccharides Interaction
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
22X
Query on 22X

Download CCD File 
A, B
(3R)-3-[(1S)-4-(acetylamino)-1-(3-chlorophenyl)-1-hydroxybutyl]-N-{(1S)-2-cyclohexyl-1-[(methylamino)methyl]ethyl}piperidine-1-carboxamide
C28 H45 Cl N4 O3
PPGUIDOUTGLYCO-MAARLIENSA-N
 Ligand Interaction
NAG
Query on NAG

Download CCD File 
B
2-acetamido-2-deoxy-beta-D-glucopyranose
C8 H15 N O6
OVRNDRQMDRJTHS-FMDGEEDCSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
22XIC50:  1.2999999523162842   nM  BindingDB
22XIC50:  16   nM  BindingDB
22XIC50 :  1.2999999523162842   nM  PDBBind
22XIC50:  1.2999999523162842   nM  Binding MOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.90 Å
  • R-Value Free: 0.261 
  • R-Value Work: 0.200 
  • R-Value Observed: 0.203 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 53.834α = 90
b = 96.94β = 90
c = 148.568γ = 90
Software Package:
Software NamePurpose
HKL-2000data collection
MOLREPphasing
REFMACrefinement
HKL-2000data reduction
HKL-2000data scaling

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Deposited Date: 2009-11-09 
  • Released Date: 2010-01-12 
  • Deposition Author(s): Wu, Z., McKeever, B.M.

Revision History 

  • Version 1.0: 2010-01-12
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance
  • Version 1.2: 2013-06-19
    Changes: Database references
  • Version 2.0: 2020-07-29
    Type: Remediation
    Reason: Carbohydrate remediation
    Changes: Atomic model, Data collection, Derived calculations, Structure summary